Cambridge Oncometrix Limited

Cambridge Oncometrix is developing a non-invasive Prostate Liquid Biopsy test for risk stratification of men suspected of prostate cancer. The test measures the chemical element profile of semen, which changes significantly when a tumour is present in the prostate.

Prostate Liquid Biopsy is non-invasive and simple to administer, and will improve treatment outcomes by diagnosing prostate cancer earlier. The test will aid identification of men who will benefit from prostate biopsy and those who could safely forgo it, which will reduce the number of invasive biopsy procedures and post-biopsy complications, improve patients’ experience and aid efficient use of NHS resources.